To hear about similar clinical trials, please enter your email below

Trial Title: Blood Flow MRI for Monitoring Brain Tumors

NCT ID: NCT01538264

Condition: Brain Tumors

Conditions: Official terms:
Brain Neoplasms

Study type: Observational

Overall status: Active, not recruiting

Study design:

Time perspective: Cross-Sectional

Summary: The investigators are studying the use of an advanced magnetic resonance imaging (MRI) technique for measuring blood flow into brain tumors. This technique does not use radioactive tracers, and it can provide high quality images that can be obtained in a standard MRI scanner.

Detailed description: Our goals are: 1. To compare the blood flow measured with this technique with measures of tumor blood vessel density in pieces of the tumor surgically removed as a normal part of clinical treatment. This will confirm a relationship between the imaging measurements and the microscopic characteristics of tumors. 2. To compare the blood flow in tumors before therapy with the concentration of choline, an indicator of cell proliferation. This choline concentration can be measured with another MRI technique. This information will demonstrate the relationship between cell proliferation and blood supply and will also determine whether the choline measurement adds additional information that is clinically necessary. 3. To determine the reproducibility of blood flow measurements in tumors. This is necessary to better understand the sensitivity of the technique to changes in flow caused by a treatment or changes in tumor vascularity. 4. To monitor changes in blood flow after initial treatment. Since sometimes tumors can reappear, the repeated measures will help determine how useful this new imaging technique is at detecting such recurring tumors.

Criteria for eligibility:

Study pop:
All subjects will be brain tumor patients recruited through the Brain Tumor Center at the Beth Israel Deaconess Medical Center.

Sampling method: Non-Probability Sample
Criteria:
Inclusion Criteria: - diagnosed with or are suspected of having a glioma Exclusion Criteria: - contraindications to MRI which may include the following 1. Pacemaker 2. MRI incompatible metal implant 3. Recently implanted vascular clip 4. History of claustrophobia 5. Metal fragment within the eye Subjects who have received nonstandard therapy may be excluded if the therapy might alter tumor blood flow or other imaging characteristic.

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Beth Israel Deaconess Medical Center

Address:
City: Boston
Zip: 02215
Country: United States

Start date: June 2006

Completion date: December 31, 2025

Lead sponsor:
Agency: Beth Israel Deaconess Medical Center
Agency class: Other

Collaborator:
Agency: National Cancer Institute (NCI)
Agency class: NIH

Source: Beth Israel Deaconess Medical Center

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT01538264

Login to your account

Did you forget your password?